Einstein Researcher Receives Grant to Study Exhaled microRNA as Cancer Biomarker | GenomeWeb

NEW YORK (GenomeWeb) – While efforts to use microRNAs as cancer biomarkers have largely focused on analyzing samples of the small, non-coding RNAs from blood or tumor tissue, an Albert Einstein College of Medicine researcher sees potential for miRNAs carried in exhaled breath.

With a two-year grant from the National Cancer Institute, Einstein's Simon Spivack is setting out to validate the results of a pilot study showing that miRNAs could not only be obtained from exhaled breath condensate (EBC), but can indicate when an individual has lung cancer before symptoms arise.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.